Palbociclib (Ibrance)

Medicine at a glance

Palbociclib is a targeted cancer medicine taken by mouth. Its verified brand name is Ibrance. It belongs to a group called CDK4/6 inhibitors and is prescribed alongside other cancer medicines selected for your situation.

Ibrance comes as tablets and capsules. Both are available in 75 mg, 100 mg and 125 mg strengths, but their food instructions differ: capsules need food; tablets can be taken with or without food. Always check the formulation on your dispensing label.

A usual cycle has 21 days of palbociclib followed by seven days without it. Blood tests guide whether the next cycle can start. The planned break applies to palbociclib; accompanying medicines may continue on a different schedule.

Seek urgent advice for fever, shaking chills, feeling suddenly unwell, unusual bleeding, or new breathing symptoms. Severe breathlessness, collapse or chest pain needs emergency assessment immediately.

What palbociclib is and how it works

Cells use proteins called cyclin-dependent kinases 4 and 6, shortened to CDK4 and CDK6, to help control division. Palbociclib blocks these proteins, making it harder for sensitive cancer cells to move into the next stage of their growth cycle.

It is a targeted treatment rather than conventional chemotherapy, but the targets also matter to some healthy cells. This explains why palbociclib can lower blood counts and cause other significant side effects. Taking treatment at home does not remove the need for close follow-up.

Palbociclib and its accompanying medicines address different growth signals. Hormone treatment may reduce oestrogen production or block its action. Some plans also include another targeted medicine. Your team will explain what each component contributes, how benefit will be assessed and which symptoms should be reported.

How the team decides whether it is suitable

Your oncologist considers the diagnosis, extent of disease, previous treatment, current symptoms, general health and applicable prescribing information. Test results are important, but no single result replaces this overall assessment.

Hormone receptor tests show whether hormones help drive the cancer. HER2 testing examines another growth-related protein. These results help determine the appropriate partner medicines. It is no longer accurate to describe every current palbociclib plan as requiring HER2-negative disease: current US information also includes a selected combination with HER2-targeted treatment. Your own plan must meet the relevant prescribing criteria.

A PIK3CA mutation test is relevant when inavolisib is being considered as a partner. This tests for a change in a growth-signalling gene; it is not a test that everybody needs simply because they receive palbociclib.

Menopausal status also matters. When required by the accompanying endocrine treatment, people whose ovaries are still producing hormones need an additional hormone-suppressing injection. Do not omit prescribed ovarian suppression. Some men also need hormone suppression with their accompanying endocrine treatment. These medicines have separate instructions and should not be omitted during palbociclib breaks unless the team says so.

Before treatment starts

Tell the team about previous low blood counts, repeated infections, breathing problems, blood clots, liver or kidney disease, and any allergies. Mention current fever, dental infection, mouth ulcers or an unhealed wound before taking the first dose.

Bring an up-to-date list of prescription medicines, non-prescription remedies, vitamins and herbal products. Include cholesterol tablets, medicines for stomach acid, antibiotics, antifungals and seizure medicines. Some interactions can substantially change palbociclib exposure.

A complete blood count checks infection-fighting cells, red blood cells and platelets. The team also assesses liver and kidney function and arranges other tests appropriate to your combination. Pregnancy testing is needed before treatment if you could become pregnant.

If inavolisib is included, blood glucose and HbA1c, a measure of longer-term glucose control, need assessment and a monitoring plan. HER2-targeted partners such as trastuzumab require heart-function assessment and follow-up. These additional checks relate to the whole treatment plan, not to a universal palbociclib-only checklist.

Before leaving, understand your start date, seven-day break, blood-test appointments and hospital urgent-contact arrangements. Ask for a written calendar if you have several medicines with different schedules.

How palbociclib is taken

Your dose and cycle

A usual starting dose is 125 mg once daily for 21 consecutive days, then seven days off, forming a 28-day cycle. Take the prescribed dose at approximately the same time each treatment day. Your oncologist may use 100 mg or 75 mg, delay a cycle or extend a break because of blood counts, side effects or an interaction.

Severe liver impairment requires a lower prescribed dose. Kidney problems still need assessment even though the product information does not require an automatic reduction for many levels of kidney impairment. Dosing evidence in people receiving dialysis is insufficient. Do not calculate your own adjustment from a laboratory result.

Treatment often continues while it is helping and remains tolerable. There is no fixed number of cycles suitable for everyone. A lower dose is a safety decision and does not, by itself, mean the cancer is worsening.

Tablets, capsules and food

Take Ibrance capsules with food, preferably a meal. Ibrance film-coated tablets can be taken with or without food. A meal may make tablets easier to fit into your routine, but it is not required for their absorption.

Swallow the medicine whole with water. Do not open or chew capsules. Do not crush, chew or split tablets. Do not take a unit that is cracked, broken or damaged. There is no routine patient-directed dispersal or feeding-tube method in the product information checked for this article. If swallowing becomes difficult, contact the oncology pharmacist before modifying the medicine.

If the pharmacy changes your formulation, confirm the dose and food instructions again. The same brand name does not mean every practical instruction is identical.

Missed doses, vomiting and extra doses

If you miss a dose, leave it out and take the next prescribed dose at the usual time. If you vomit after taking palbociclib, do not take a replacement dose that day. Do not double up, extend the 21-day course or shorten the break to make up doses yourself.

Record what happened and tell the team if missed doses or vomiting recur. Partner medicines can have different missed-dose rules; do not apply palbociclib’s rule automatically to them. If you take too much, obtain urgent medical advice immediately and take the medicine packaging with you.

Storage and handling

Keep medicine in its original packaging, away from children and pets. US Ibrance instructions specify storage at 20–25°C (68–77°F), with permitted short excursions; EU tablets need their original blister to protect from moisture. Follow your actual pack’s instructions, especially when travelling in hot weather. Do not store tablets loose in a damp bathroom or leave them in a hot vehicle.

Wash your hands after handling the medicine and avoid contact with damaged contents. Return unused supplies to the dispensing pharmacy according to its instructions rather than sharing them or putting them into household drains.

Monitoring and checking whether treatment is working

The standard blood-count schedule is before starting treatment, at the beginning of each cycle, and on day 15 of the first two cycles. Extra tests are needed if counts fall or you become unwell. The mid-cycle check matters because a low count may cause no symptoms.

After six cycles, people whose neutrophil reductions have remained only mild or moderate may have blood counts every three months, before a cycle starts, with additional checks as clinically needed. This is a clinician-directed option, not permission to stop attending monthly appointments yourself.

Liver and kidney blood tests, symptoms, weight and other checks are reviewed according to your circumstances and partner medicines. Additional glucose monitoring is essential with inavolisib; heart monitoring is important with trastuzumab-containing treatment.

Scans, examination and symptom changes help assess cancer control. Blood-count changes mainly show treatment safety and are not a measure of whether palbociclib is working against the cancer. Report new or worsening symptoms between appointments rather than waiting for the next scan.

Common side effects and practical management

Lower blood counts

Neutrophils are white blood cells that help fight infection. A low neutrophil count, called neutropenia, is very common with palbociclib and often leads to temporary treatment changes. Do not assume infection is harmless because a planned break has started. Infection can become serious quickly and needs prompt assessment.

Low red blood cells, or anaemia, can cause fatigue, dizziness, palpitations and breathlessness. Report these symptoms so the team can decide whether blood tests or treatment are needed. Low platelets can cause easy bruising, nosebleeds or gum bleeding. Avoid starting aspirin or anti-inflammatory painkillers without checking, and report unusual bleeding.

Tiredness and reduced stamina

Fatigue may be related to treatment, anaemia, sleep, nutrition or the cancer itself. Plan demanding tasks for better-energy periods, take short rests and remain gently active when able. New fatigue accompanied by fever, breathlessness, faintness or a racing heart needs assessment rather than simply more rest.

Mouth soreness

Mouth inflammation can make eating and drinking uncomfortable. Use a soft toothbrush, keep the mouth clean and choose bland, soft foods if it is sore. Avoid alcohol-containing mouthwashes and foods that sting. Tell the team early about ulcers, white patches, pain or difficulty swallowing; prescription mouth care may help. Being unable to drink needs urgent advice.

Nausea, diarrhoea and appetite changes

Take prescribed anti-sickness medicines as directed. Smaller meals may be easier, and a dietitian can help if appetite or weight is falling. For diarrhoea, drink regularly and follow the team’s plan for replacement fluids and medicines. Seek urgent advice for repeated watery stools, blood, significant abdominal pain, dizziness or reduced urine. Diarrhoea can be more troublesome with some partner treatments, so report its pattern accurately.

Hair, skin and eye changes

Hair can thin or become more fragile. Gentle hair care may reduce discomfort, and support is available if changes affect confidence. Dry or itchy skin can improve with a simple moisturiser; persistent rash should be assessed.

Dry eyes, watering or blurred vision can occur. Discuss suitable lubricating drops and report persistent changes. Eye pain, marked redness or sudden loss of vision requires urgent assessment. Red, painful palms or soles also deserve attention before they interfere with walking or using your hands.

Less common but important side effects

Lung inflammation

Palbociclib can cause inflammation within the lungs, called pneumonitis or interstitial lung disease. It can be severe and has occasionally been fatal. New or worsening breathlessness, a dry cough, low oxygen or chest discomfort needs immediate contact with the treating team. Infection, a clot and other causes can feel similar, so symptoms need examination rather than self-diagnosis.

If the team suspects pneumonitis, palbociclib must be interrupted immediately while it is assessed. Seek urgent advice before taking another dose when new breathing symptoms develop. Severe confirmed lung inflammation requires permanent discontinuation. Do not restart after a lung-related interruption until the oncologist has given clear instructions.

Blood clots

Clots in a leg vein or the lungs have been reported with palbociclib treatment. Painful swelling, redness or warmth affecting one limb needs urgent assessment. Sudden breathlessness, chest pain, coughing blood or collapse is an emergency. Do not start aspirin or a blood thinner yourself; prevention and treatment depend on individual risks.

Significant skin or muscle problems

Unusual inflammatory skin reactions can cause target-like spots, scaly patches or a rash associated with fever or joint pain. Report these promptly. Extensive blistering, peeling or mouth involvement needs urgent medical assessment.

Palbociclib can interact with certain statins, including simvastatin and atorvastatin. Serious muscle breakdown has been reported with these combinations. Severe unexplained muscle pain or weakness, particularly with dark urine, needs urgent advice. Have the combination checked rather than stopping essential long-term treatment on your own.

Effects contributed by partner medicines

Inavolisib can cause important high blood glucose, mouth inflammation and diarrhoea. High glucose can lead to a dangerous build-up of acids, called ketoacidosis. Excessive thirst or urination needs prompt advice; marked drowsiness, vomiting with dehydration or difficulty breathing requires emergency assessment. Trastuzumab-containing treatment adds heart-related risks: new swelling, breathlessness when lying down or rapid weight gain should be reported promptly. Each accompanying medicine’s information remains important even if palbociclib is the medicine you take at home.

Other medicines, supplements and vaccinations

Palbociclib is processed partly through a liver enzyme called CYP3A. Strong blockers of this enzyme, such as some antifungals and clarithromycin, can raise its level. Strong enzyme activators, including rifampicin, carbamazepine and phenytoin, can lower it. The team usually avoids these combinations or makes a specific prescribing adjustment.

Avoid grapefruit and grapefruit juice. Do not take St John’s wort. Check herbal mixtures and supplements before use, even if advertised as natural. Palbociclib can also raise levels of some other medicines, including certain sedatives, strong painkillers and transplant medicines. Show the medicine list before an operation, dental procedure or new prescription.

Acid-reducing medicines need a formulation-specific check. Ibrance tablets are not meaningfully affected by the tested proton-pump inhibitor interaction. Capsule absorption can fall substantially when taken fasting with a proton-pump inhibitor; their food requirement remains essential. The labels do not provide a universal several-hour separation rule for all Ibrance products. Do not stop necessary stomach protection or invent a timing workaround: have the pharmacist check the actual formulation and prescription.

Discuss vaccines with the oncology team. Live vaccines are generally avoided during immune-suppressing cancer treatment. Non-live vaccines may be recommended, although response can be reduced; timing should fit your treatment and blood counts.

Everyday life during treatment

Many people continue some usual activities, but energy and infection risk vary across cycles. Handwashing, avoiding close contact with people who are clearly unwell and careful food preparation are practical precautions. You do not need to assume that all normal social contact is unsafe.

Eat a varied diet as tolerated and drink enough to avoid dehydration unless you have a prescribed fluid restriction. Discuss alcohol if you have liver problems, nausea or interacting medicines. Short walks and other manageable activity can help maintain strength; stop and seek advice for new chest symptoms or unusual breathlessness.

Do not drive if fatigue, dizziness or blurred vision affects your safety. Work adjustments, flexible hours and help with household tasks may be useful. Plan travel around blood tests, prescriptions and access to urgent care, and carry medicines in their labelled packaging.

Tell dentists and surgeons about palbociclib before treatment. Blood counts and infection risk may affect the timing of procedures. Discuss sexual comfort, vaginal dryness and emotional concerns openly; supportive care can help without requiring you to manage these problems alone.

Fertility, contraception, pregnancy and breastfeeding

Palbociclib can harm a developing baby. If pregnancy is possible, a pregnancy test is needed before starting and effective contraception is required during treatment. For patients who can become pregnant, US and EU palbociclib information specifies at least three weeks after the last dose.

For male patients with a partner who could become pregnant, US information specifies contraception during treatment and for at least three months afterwards; EU information specifies at least 14 weeks. The team should provide the applicable stop date. EU information discusses barrier approaches, including double-barrier contraception. Choose a method with your cancer team rather than assuming a hormonal contraceptive is suitable for your situation.

These palbociclib intervals must not shorten precautions required by other medicines. For example, trastuzumab requires contraception for patients who could become pregnant for seven months after its last dose. Fulvestrant requires female contraception for one year after treatment in US information and two years in European information. Other partners may also require longer precautions. Report a suspected pregnancy in you or your partner promptly.

Do not breastfeed during palbociclib treatment. US information continues this restriction for three weeks after the last dose; EU information prohibits breastfeeding during treatment without giving the same fixed restart interval. Fulvestrant’s US information prohibits breastfeeding for one year after its last dose; European information prohibits it during treatment without specifying a fixed restart interval. Confirm when feeding could safely resume after considering every treatment in your plan.

Palbociclib may affect male fertility. Discuss sperm storage before starting if future parenthood matters. The effects of the whole treatment plan on fertility deserve discussion for all patients; absence of periods does not reliably prove infertility or remove contraception requirements.

After treatment finishes

Ask which accompanying medicines continue and which monitoring appointments remain necessary. Blood counts may need follow-up until they recover. Infection, breathing symptoms or unusual bleeding still require assessment after the last tablet or capsule; stopping treatment does not make a new symptom unimportant.

Continue contraception and breastfeeding precautions for the full agreed period. Return unused medicine to the pharmacy and keep a record of treatment dates and significant side effects. If palbociclib is being stopped because it is no longer controlling the cancer, the team will discuss other options and supportive care based on your current circumstances.

Frequently asked questions